Company profile
Rallybio Corporation
NASDAQ: RLYB · Healthcare · Biotechnology
#881 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
47DFH 54DQ 40GM —SS 36
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, operating margin
Methodology →Revenue TTM
$858.0k
Rev growth YoY (TTM)
+1.2%
Net income (FY)
-$9.0M
Employees
9
as of 2026-08-18
Market cap
$89.8M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$858.0k$858.0k2025
Net income-$9.0M-$9.0M2025
Operating income-$33.1M-$33.1M2025
Total assets$62.3M$62.3M2025
Liabilities$4.3M$4.3M2025
Equity$58.0M$58.0M2025
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration And License Revenue52%
License48%
By geography
Not disclosed.
The read
What is Rallybio Corporation’s revenue?
Rallybio Corporation booked $858.0k in FY2025 revenue, growing 43% year over year — faster than most Healthcare companies we track, at a -1046.4% net margin.
Peers · Healthcare
InVitro International76B+Profile Solutions, Inc.——IGC Pharma, Inc.45DUniversal Ibogaine Inc.——Advantis Corp.——Imagenetix, Inc.——Neighbors
New Haven →Key facts
CEOStephen Uden
SectorHealthcare
IndustryBiotechnology
HeadquartersNew Haven, CT
ExchangeNASDAQ: RLYB
Employees9
IPO date2021-07-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.